


EMLc

ATC codes: **L01XA02**

Indication	Retinoblastoma <b>ICD11 code: 2D52.2</b>
INN	Carboplatin
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 50 mg per 5 mL ; 150 mg per 15 mL ; 450 mg per 45 mL ; 600 mg per 60 mL
EML status history	First added in 2009 ( <b>TRS 958</b> ) Changed in 2015 ( <b>TRS 994</b> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <b>about patents</b> . 

Tags

Cancer

Wikipedia

**Carboplatin** 

DrugBank

**Carboplatin** 

### Summary of evidence and Expert Committee recommendations

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML and EMLc for use in treatment protocols for retinoblastoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of the treatment protocols for retinoblastoma is attached.

Expert Committee report 